CUV

1.85%

$13.28 clinuvel pharmaceuticals limited

I agree with your revenue predictions and SP. It is already $9...

First 11 Last

Share
Profile

Follow
kar18na

1,181 Posts.

12

13/01/18

17:52

Post #: 30281639
Share

Originally posted by cuv101 ↑

18 months ago when the price of the implant was discovered I made some predictions regarding expected sales and share price.
Since then the share price has almost doubled so I am not riddled with guilt if anyone bought on the strength of my post however it has not proceeded as I had hoped for. Nothing ever does!

The German rollout has been, and remains an issue. Pricing negotiations were “difficult” however ultimately successful but much more unexpected was the log jam encountered at the doctor patient level. With patients being turned away due to lack of resources, this has resulted in a much slower take up in the largest non US market. This is expected to only slowly resolve over the foreseeable future tempering revenue expectations.

UK was expected to be done and dusted without incident. The HST/STA/HST debacle cost time with NICE recently delivering a negative preliminary assessment. Clinuvel’s second biggest market outside of the US is seemingly no closer to reimbursement also tempering expectations.

Switzerland, proceeded in the courts with Clinuvel escaping with a bloody nose and damaged reputation having been tarnished with the greedy pharma brush. A problem which seemingly could have been avoided with Swissmedic approval.

Italy has been slow to adopt the new price and some concessions by Clinuvel were given with an agreement to pay for the screening required as part of the EMA dictated post approval safety study.

Austria seems to be treating patients in the single digits and is of little consequence.

Holland is the shining light, with over 100 patients receiving treatment paying full price.

There remains no news from other EU countries or Norway. Wolgen in the AR has reported that a further 6 countries will be targeted in 2018. This has been perhaps disappointing. 5 US patients travel to Switzerland to receive the implant at an unknown price, this is subsidised by US insurance.

What is extremely positive is the reported rate of re-treatment with over 90% of treated patients re-attending for treatment in the second year. This is consistent with the long term data from Switzerland and Italy where the numbers actually increased over the 8 year observation period. This is outstanding for any intervention that treats a symptom only.

I was hopeful of a revenue of $100 million this year, 2018 with over 1000 patients being treated. Last year it was 17 million and with the issues discussed (no UK patients, very few in Germany) clearly Clinuvel wont get anywhere near 100 million this year. $5.5 million in the first quarter with reduced revenues expected for the next 2 quarters, maybe $20-25 million revenue this year. Expenses should be reasonably stable at 9 million. My predicted PE of 50 seems to be about right so a market cap of around 550 - 800 million is still achievable and reasonable IMO, share price $11 - $16. Still plenty of upside and limited downside.

Expand

I agree with your revenue predictions and SP. It is already $9 at the start of 2018.
This company is only going to get bigger and better.
Nice cash balance, cash flow positive on operations, good revenues, orphan drug so no competition, list goes on.
I only wish I had taken my own advice earlier lol.
I hope that we do not get taken out too early, but management seem to have their own value on the company so I don't think that will happen.

CUV Price at posting: $9.10 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

HotCopper Highlights: Your most watched stocks for Week 46, 2024

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

First 11 Last

Add CUV (ASX) to my watchlist

(20min delay)
Last $13.28		Change -0.250(1.85%)		Mkt cap ! $664.8M

Open	High	Low	Value	Volume
$13.55	$13.62	$13.25	$1.157M	86.45K

Buyers (Bids)

No.	Vol.	Price($)
1	227	$13.28

Sellers (Offers)

Price($)	Vol.	No.
$13.42	228	1

View Market Depth

No.	Vol.	Price($)
4	3077	13.250
1	10	13.240
1	500	13.230
1	200	13.220
7	2791	13.200

Price($)	Vol.	No.
13.500	800	1
13.530	700	1
13.550	2500	1
13.890	729	1
14.000	2020	2

Last trade - 16.10pm 15/11/2024 (20 minute delay)

CUV (ASX) Chart

I agree with your revenue predictions and SP. It is already $9...

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

HotCopper Highlights: Your most watched stocks for Week 46, 2024

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I agree with your revenue predictions and SP. It is already $9...

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

HotCopper Highlights: Your most watched stocks for Week 46, 2024

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News